Page 76 - Demo

Chapter 37445. Müller AR, Brands MM, van de Ven PM, Roes KC, Cornel MC, van Karnebeek CD, et al. The Power of 1: Systematic Review of N-of-1 Studies in Rare Genetic Neurodevelopmental Disorders. Neurology. 2021.46. Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT. The n-of-1 randomized controlled trial: Clinical usefulness. Our three-year experience. Ann Intern Med. 1990.47. Stunnenberg BC, Deinum J, Nijenhuis T, Huysmans F, van der Wilt GJ, van Engelen BGM, et al. N-of-1 Trials: Evidence-Based Clinical Care or Medical Research that Requires IRB Approval? A Practical Flowchart Based on an Ethical Framework. Healthcare. 2020.48. Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. What ever happened to N-of-1 trials? Insiders’ perspectives and a look to the future. Milbank Q. 2008.49. Backman CL, Harris SR. Case studies, single-subject research, and N of 1 randomized trials: Comparisons and contrasts. Am J Phys Med Rehabil. 1999.50. Gaasterland CMW, Jansen-van der Weide MC, Vroom E, Leeson-Beevers K, Kaatee M, Kaczmarek R, et al. The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. Health Policy (New York). 2018. Annelieke Muller sHL.indd 74 14-11-2023 09:07